Authors
Latest:
Advanced bladder cancer patients could keep their bladder under new treatment regime, clinical trial showsAn approach combining chemotherapy and immunotherapy could help preserve quality of life.
Latest:
Urine-based test demonstrates consistent efficacy in NMIBC surveillanceThe Bladder EpiCheck test received FDA 510(k) clearance in May 2023 for use in patients with NMIBC.
Latest:
Emerging Therapies for Metastatic Castration-Resistant Prostate CancerRobert Dreicer, MD, describes the future of metastatic castration-resistant prostate cancer.
Latest:
Future Perspectives in the Treatment of Patients With Urinary StonesDrs Bechis and Semins discuss future developments in urinary stone management, emphasizing the potential for improved vacuum aspiration devices, combined intravenous and PCNL surgeries, and the hope for medications to dissolve stones.
Latest:
Demystifying Vector-Based Intravesical Gene Therapy for NMIBC: A New FrontierNeal Shore, MD, FACS, is a U.S. Chief Medical Officer at GenesisCare USA and Medical Director of the Carolina Urologic Research Center. He also was an investigator on the Phase 2 and 3 studies in the clinical trial program for nadofaragene firadenovec-vncg.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Diversity in Urology: Progress made, but there is more work to be doneKelvin Moses, MD, PhD, interviews Tracy M. Downs, MD, about progress and remaining challenges regarding diversity, equity, and inclusion in the field of urology.
Latest:
What steps can physicians take to overcome barriers to health equity?“Things we have control over are ourselves, our care team, and to some extent, our care model,” said Sarah Candler, MD.
Latest:
Urologists strive to personalize active surveillance plans for patients with low-risk prostate cancer"Patients shouldn’t be making the decision to do active surveillance without understanding what that means and what their other options are,” one panelist said.
Latest:
Current Shortcomings in the Modern Urology Practice Management LandscapeA urologist practicing in California defines the remaining general and region-specific challenges he faces in managing his practice and his hopes for future solutions.
Latest:
Closing Thoughts on the Impact of PSMA-PET Imaging in Prostate CancerExperts summarize how the use of PSMA-PET imaging has impacted the field to date and share their hopes for the future.
Latest:
Continued Advances and Unmet Needs in PSMA-Based Imaging for Prostate CancerExperts Naveen Kella, MD, and Dr. Shadi Esfahani, MD, MPH, consider the continued impact of PSMA PET imaging on prostate cancer management and emerging modalities that could revolutionize patient care.
Latest:
Balancing the benefits and risks of AI in health care“The potential benefits of incorporating AI into health care are numerous but like every technology, AI comes with risks that must be managed if the benefits of these tools are to outweigh the potential costs,” writes cybersecurity expert Jon Moore.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
The safety and oncologic benefits of transperineal vs transrectal MRI-guided prostate biopsy"These studies, taken together, offer important insight into the direction we should be heading in prostate cancer diagnosis: toward a targeted-only TP biopsy," write Tarik Benidir, MD, and Zeyad Schwen, MD.
Latest:
Race-based adjustment of eGFR: Current opinions and impact on urologic oncology“As other factors such as access to care, socioeconomic conditions, patient preference, and other unknown confounders might have played a role in the observed disparity, it is still unclear whether overestimating the postoperative eGFR of Black patients contributes to the lower use of nephron-sparing approaches in this population,” the authors write.
Latest:
Update on advanced imaging in prostate cancerAdvances allow for more accurate detection of metastatic disease.
Latest:
UroView: Gallium 68 PSMA–Targeted PET Imaging in Prostate Cancer: Staging and OutcomesThis article features insights from Phillip Kuo, MD, PhD, and Andre Abreu, MD, on gallium 68 PSMA-targeted PET imaging in prostate cancer.
Latest:
Optimizing Care Collaboration in Advanced Prostate CancerExplore strategies for seamless coordination between urologists and medical oncologists to ensure uninterrupted, patient-focused care in prostate cancer treatment.
Latest:
Medical software should be chosen based on your practice’s life cycle stageAt each stage, health care providers have different priorities and goals, and the choice of medical software solutions should be made accordingly.
Latest:
The current state of adjuvant radiotherapy post prostatectomy: 3 take-home messages"If your practice does not closely monitor patients and send them for early salvage radiotherapy when their PSA is 0.1 or 0.2 ng/mL, it is likely that adjuvant radiotherapy is superior," Daniel E. Spratt, MD, writes.
Latest:
Presentation, diagnosis, and management of a rare case of urachal adenocarcinoma"Urachal carcinoma is a rare and aggressive malignancy. The low incidence of the disease results in limited large-scale clinical trials that could provide standardized guidelines for its diagnosis and management," write Christopher Pieczonka, MD, and Peter Fioramonti, BS.
Latest:
Subgroup data sustain enzalutamide PFS benefit in nmCRPCNo new safety signals were reported with the androgen receptor pathway inhibitor.
Latest:
Continued Advances and Unmet Needs in PSMA-Based Imaging for Prostate CancerExperts Naveen Kella, MD, and Dr. Shadi Esfahani, MD, MPH, consider the continued impact of PSMA PET imaging on prostate cancer management and emerging modalities that could revolutionize patient care.
Latest:
Minimizing incontinence after radical prostatectomy: Lessons learned"I've worked in 3 different countries, I've seen dozens of people doing robotic radical prostatectomy...so my current practice is kind of a “best of” what I have seen and learned," says Ricardo Soares, MD.
Latest:
Neoadjuvant combo boosts MRD negativity rates in high-risk prostate cancerAdding apalutamide to the hormone therapy degarelix in the neoadjuvant setting increased the likelihood of achieving minimal residual disease negativity in patients with high-risk prostate cancer after radical prostatectomy.
Latest:
Physician Commentary: Do EHR upgrades really enhance patient care?"Clinicians, now more than ever, have many data entry duties. The clinical encounter’s efficiency is dictated by the ease of the EHR," write Jesse D. Bracamonte, DO, FAAFP, and Michael Underhill, DO.
Latest:
Case review: An incidentally discovered renal massAn expert panel discusses the case of a 65-year-old Caucasian male who is noted to have an incidental 3-cm right renal mass, enhancing on a contrasted CT scan as part of a routine follow-up for his metastatic castration-resistant prostate cancer, diagnosed in 2017 and currently undergoing therapy.
Latest:
Expert explains how to fully optimize EHRsRecent advances in technology make it possible to access and harness the vast amounts of clinical data EHRs have produced.
Latest:
Exploratory analysis identifies blood-based biomarkers that may predict treatment outcomes in urothelial carcinomaThe exploratory analysis may have showcased the benefit of testing for tertiary lymphoid structures.
